Intravitreal methotrexate as adjunctive, palliative therapy in intraocular T-cell lymphoma.
To report on the rapid and sustained effect following injection of intravitreal methotrexate (IVTMTX) in intraocular T-cell lymphoma. Report of 2 cases. A young male with natural killer/T-cell lymphoma presented with infiltrative nodular iridocyclitis and received a single IVTMTX. An elderly female with peripheral T-cell lymphoma presented with a hypopyon, infiltrative iridocyclitis, and choroidal effusions and received 3 IVTMTX over 4 months. Both patients responded well after the first injection, with resolution of signs within 1 week and improvement in vision. IVTMTX may be effective as a palliative, vision-restoring measure in patients with systemic T-cell lymphoma.